nach oben

15.04.2024 | Review Article

The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders

verfasst von: J. H. Shazia Fathima, Selvaraj Jayaraman, Ramya Sekar, Nazmul Huda Syed

Erschienen in: Odontology

Einloggen, um Zugang zu erhalten

Abstract

Oral premalignant disorders (OPMDs) are a group of potentially malignant conditions that pose a significant health burden globally. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as crucial regulators of gene expression and have been implicated in various biological processes, including carcinogenesis. This review synthesizes existing knowledge to provide a comprehensive understanding of the molecular mechanisms underlying OPMDs and to highlight the potential of miRNAs as promising biomarkers and therapeutic targets. Additionally, this review seeks to explore the potential of miRNA-based diagnostic biomarkers for early detection of OPMDs in the current literature on miRNAs in OPMDs, examining their involvement in disease pathogenesis, diagnostic potential, and therapeutic implications. Dysregulated miRNAs can target genes involved in critical cellular processes, such as cell cycle regulation, apoptosis, and DNA repair, leading to disease progression. Notably, miR-21, miR-31, miR-135b, and miR-486-5p have shown promise as potential biomarkers for early detection of oral premalignant lesions. Furthermore, the paper discusses the therapeutic implications of miRNAs in OPMDs. Preclinical studies have demonstrated the efficacy of miRNA-targeted therapies, such as miRNA mimics and inhibitors, in suppressing the growth of oral premalignant lesions. Early-phase clinical trials have shown promising results, indicating the potential for personalized treatment approaches. The findings underscore the importance of understanding the molecular mechanisms underlying these disorders and provide insights for the development of improved diagnostic and therapeutic strategies. However, they pose certain limitations given their intrinsic variability in expression profiles, the need for optimized isolation and detection methods, and potential hurdles in transitioning from preclinical success to clinical applications. Thus, future clinical studies are warranted to fully exploit the potential of miRNAs in the management of OPMDs.

Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–16. https://doi.org/10.1016/j.oraloncology.2008.06.002.CrossRefPubMed

Sankaranarayanan R, Ramadas K, Qiao Y. Managing the changing burden of cancer in Asia. BMC Med. 2014;12:3. https://doi.org/10.1186/1741-7015-12-3.CrossRefPubMedPubMedCentral

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. https://doi.org/10.1016/S0092-8674(04)00045-5.CrossRefPubMed

Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. https://doi.org/10.1038/sigtrans.2015.4.CrossRefPubMedPubMedCentral

Shi Z, Johnson JJ, Stack MS. Detecting MicroRNA in human cancer tissues with fluorescence in situ hybridization. In: Kolpashchikov DM, Gerasimova YV, editors. Nucleic acid detect. Methods Protoc. Totowa: Humana Press; 2013. p. 19–27.CrossRef

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24. https://doi.org/10.1038/nrm3838.CrossRefPubMed

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54. https://doi.org/10.1016/0092-8674(93)90529-y.CrossRefPubMed

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403:901–6. https://doi.org/10.1038/35002607.CrossRefPubMed

Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–8. https://doi.org/10.1126/science.1064921.CrossRefPubMed

10.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66. https://doi.org/10.1038/nrc1997.CrossRefPubMed

11.

Gorenchtein M, Poh CF, Saini R, Garnis C. MicroRNAs in an oral cancer context—from basic biology to clinical utility. J Dent Res. 2012;91:440–6. https://doi.org/10.1177/0022034511431261.CrossRefPubMed

12.

Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci. 2006;103:2257–61. https://doi.org/10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral

13.

Manikandan M, Deva Magendhra Rao AK, Arunkumar G, Manickavasagam M, Rajkumar KS, Rajaraman R, et al. Oral squamous cell carcinoma: microRNA expression profiling and integrative analyses for elucidation of tumourigenesis mechanism. Mol Cancer. 2016;15:28. https://doi.org/10.1186/s12943-016-0512-8.CrossRefPubMedPubMedCentral

14.

Fluorescence In Situ Hybridization for MicroRNA Detection in Archived Oral Cancer Tissues—PMC n.d. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359729/ (accessed October 2, 2023).

15.

Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986;61:373–81. https://doi.org/10.1016/0030-4220(86)90422-6.CrossRefPubMed

16.

Warnakulasuriya S, Johnson Newell W, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575–80. https://doi.org/10.1111/j.1600-0714.2007.00582.x.CrossRefPubMed

17.

Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021;27:1862–80. https://doi.org/10.1111/odi.13704.CrossRefPubMed

18.

Report of National Cancer Registry Programme 2020 n.d. https://ncdirindia.org/All_Reports/Report_2020/default.aspx (accessed September 25, 2023).

19.

Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z, et al. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018;18:911. https://doi.org/10.1186/s12885-018-4806-7.CrossRefPubMedPubMedCentral

20.

Liu C-J, Tsai M-M, Hung P-S, Kao S-Y, Liu T-Y, Wu K-J, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010;70:1635–44. https://doi.org/10.1158/0008-5472.CAN-09-2291.CrossRefPubMed

21.

Liu W, Zhao X, Zhang Y-J, Fang G-W, Xue Y. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma. J Int Med Res. 2018;46:975–83. https://doi.org/10.1177/0300060517734114.CrossRefPubMed

22.

Wang L, Chen W, Zha J, Yan Y, Wei Y, Chen X, et al. miR-543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5. Oncol Rep. 2019;42:973–90. https://doi.org/10.3892/or.2019.7230.CrossRefPubMedPubMedCentral

23.

Chen H, Liu X, Jin Z, Gou C, Liang M, Cui L, et al. A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma. Am J Cancer Res. 2018;8:1403–13.PubMedPubMedCentral

24.

Uma Maheswari TN, Nivedhitha MS, Ramani P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. Braz Oral Res. 2020;34: e002. https://doi.org/10.1590/1807-3107bor-2020.vol34.0002.CrossRefPubMed

25.

Chang Y-A, Weng S-L, Yang S-F, Chou C-H, Huang W-C, Tu S-J, et al. A three–MicroRNA signature as a potential biomarker for the early detection of oral cancer. Int J Mol Sci. 2018;19:758. https://doi.org/10.3390/ijms19030758.CrossRefPubMedPubMedCentral

26.

Liu C-M, Liao Y-W, Hsieh P-L, Yu C-H, Chueh PJ, Lin T, et al. miR-1246 as a therapeutic target in oral submucosa fibrosis pathogenesis. J Formos Med Assoc. 2019;118:1093–8. https://doi.org/10.1016/j.jfma.2019.02.014.CrossRefPubMed

27.

Zheng L, Jian X, Guo F, Li N, Jiang C, Yin P, et al. miR-203 inhibits arecoline-induced epithelial-mesenchymal transition by regulating secreted frizzled-related protein 4 and transmembrane-4 L six family member 1 in oral submucous fibrosis. Oncol Rep. 2015;33:2753–60. https://doi.org/10.3892/or.2015.3909.CrossRefPubMed

28.

Prasad SR, Pai A, Shyamala K, Yaji A. Expression of salivary miRNA 21 in oral submucous fibrosis (OSMF): an observational study. Microrna Shariqah United Arab Emir. 2020;9:295–302. https://doi.org/10.2174/2211536609666200127143749.CrossRef

29.

Du J, Gao R, Wang Y, Nguyen T, Yang F, Shi Y, et al. MicroRNA-26a/b have protective roles in oral lichen planus. Cell Death Dis. 2020;11:15. https://doi.org/10.1038/s41419-019-2207-8.CrossRefPubMedPubMedCentral

30.

Ma H, Wu Y, Yang H, Liu J, Dan H, Zeng X, et al. MicroRNAs in oral lichen planus and potential miRNA–mRNA pathogenesis with essential cytokines: a review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:164–73. https://doi.org/10.1016/j.oooo.2016.03.018.CrossRefPubMed

31.

Tao Y, Ai R, Hao Y, Jiang L, Dan H, Ji N, et al. Role of miR-155 in immune regulation and its relevance in oral lichen planus. Exp Ther Med. 2019;17:575–86. https://doi.org/10.3892/etm.2018.7019.CrossRefPubMed

32.

Ahmadi-Motamayel F, Bayat Z, Hajilooi M, Mahdavinezhad A, Samie L, Solgi G. Evaluation of the miRNA-146a and miRNA- 155 expression levels in patients with oral lichen planus 2017.

33.

Chen J, Du G, Wang Y, Shi L, Mi J, Tang G. Integrative analysis of mRNA and miRNA expression profiles in oral lichen planus: preliminary results. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124:390-402.e17. https://doi.org/10.1016/j.oooo.2017.05.513.CrossRefPubMed

34.

Zhang W-Y, Liu W, Zhou Y-M, Shen X-M, Wang Y-F, Tang G-Y. Altered microRNA expression profile with miR-27b down-regulation correlated with disease activity of oral lichen planus. Oral Dis. 2012;18:265–70. https://doi.org/10.1111/j.1601-0825.2011.01869.x.CrossRefPubMed

35.

Stasio DD, Mosca L, Lucchese A, Cave DD, Kawasaki H, Lombardi A, et al. Salivary mir-27b expression in oral lichen planus patients: a series of cases and a narrative review of literature. Curr Top Med Chem. 2019;19:2816–23. https://doi.org/10.2174/1568026619666191121144407.CrossRefPubMed

36.

Ghallab NA, Kasem RF, El-Ghani SFA, Shaker OG. Gene expression of miRNA-138 and cyclin D1 in oral lichen planus. Clin Oral Investig. 2017;21:2481–91. https://doi.org/10.1007/s00784-017-2091-5.CrossRefPubMed

37.

Zhao B, Xu N, Li R, Yu F, Zhang F, Yang F, et al. Vitamin D/VDR signaling suppresses microRNA-802-induced apoptosis of keratinocytes in oral lichen planus. FASEB J. 2019;33:1042–50. https://doi.org/10.1096/fj.201801020RRR.CrossRefPubMed

38.

Wang L, Wu W, Chen J, Li Y, Xu M, Cai Y. miR-122 and miR-199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway. Int J Mol Med. 2019;43:1373–81. https://doi.org/10.3892/ijmm.2019.4068.CrossRefPubMedPubMedCentral

39.

Brito JAR, Gomes CC, Guimarães ALS, Campos K, Gomez RS. Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia. J Oral Pathol Med. 2014;43:211–6. https://doi.org/10.1111/jop.12112.CrossRefPubMed

40.

Mehterov N, Sacconi A, Pulito C, Vladimirov B, Haralanov G, Pazardjikliev D, et al. A novel panel of clinically relevant miRNAs signature accurately differentiates oral cancer from normal mucosa. Front Oncol 2022;12.

41.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513–8. https://doi.org/10.1073/pnas.0804549105.CrossRefPubMedPubMedCentral

42.

Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011;8:706–13. https://doi.org/10.4161/rna.8.5.16154.CrossRefPubMedPubMedCentral

43.

Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122:1630–7. https://doi.org/10.1038/s41416-020-0802-1.CrossRefPubMedPubMedCentral

44.

Chitturi Suryaprakash RT, Shearston K, Farah CS, Fox SA, Iqbal MM, Kadolsky U, et al. A novel preclinical in vitro 3D model of oral carcinogenesis for biomarker discovery and drug testing. Int J Mol Sci. 2023;24:4096. https://doi.org/10.3390/ijms24044096.CrossRefPubMedPubMedCentral

45.

Ottman R, Ganapathy K, Lin H-Y, Osterman CD, Dutil J, Matta J, et al. Differential expression of miRNAs contributes to tumor aggressiveness and racial disparity in African American men with prostate cancer. Cancers. 2023;15:2331. https://doi.org/10.3390/cancers15082331.CrossRefPubMedPubMedCentral

46.

Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics. 2014;7:53. https://doi.org/10.1186/1755-8794-7-53.CrossRefPubMedPubMedCentral

47.

Cheng M, Wang B, Yang M, Ma J, Ye Z, Xie L, et al. microRNAs expression in relation to particulate matter exposure: a systematic review. Environ Pollut. 2020;260: 113961. https://doi.org/10.1016/j.envpol.2020.113961.CrossRefPubMed

48.

Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9:276. https://doi.org/10.3390/cells9020276.CrossRefPubMedPubMedCentral

49.

Jeyaseelan K, Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets. 2007;11:1119–29. https://doi.org/10.1517/14728222.11.8.1119.CrossRefPubMed

50.

Peng J, Zhao J-S, Shen Y-F, Mao H-G, Xu N-Y. MicroRNA expression profiling of lactating mammary gland in divergent phenotype swine breeds. Int J Mol Sci. 2015;16:1448–65. https://doi.org/10.3390/ijms16011448.CrossRefPubMedPubMedCentral

51.

Jet T, Gines G, Rondelez Y, Taly V. Advances in multiplexed techniques for the detection and quantification of microRNAs. Chem Soc Rev. 2021;50:4141–61. https://doi.org/10.1039/D0CS00609B.CrossRefPubMed

52.

Latini A, Borgiani P, Novelli G, Ciccacci C. miRNAs in drug response variability: potential utility as biomarkers for personalized medicine. Pharmacogenomics. 2019;20:1049–59. https://doi.org/10.2217/pgs-2019-0089.CrossRefPubMed

Titel: The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders
verfasst von: J. H. Shazia Fathima
Selvaraj Jayaraman
Ramya Sekar
Nazmul Huda Syed
Publikationsdatum: 15.04.2024
Verlag: Springer Nature Singapore
Erschienen in: Odontology
Print ISSN: 1618-1247
Elektronische ISSN: 1618-1255
DOI: https://doi.org/10.1007/s10266-024-00934-0

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders

Abstract

Neu im Fachgebiet Zahnmedizin

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Parodontalbehandlung verbessert Prognose bei Katheterablation

Newsletter

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Zahnmedizin

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Parodontalbehandlung verbessert Prognose bei Katheterablation

Newsletter